Menu visibility control



Startup Surgery

Most Recent


Iris Capital launches €250m European tech investment fund


Startup Weekly: Welsh tech accelerator calls for applications, Virgin StartUp partners with WeWork and more

Tech City Voices

Culture. There’s no app for that, Kalanick

Press Releases

‘Connected finance’ app Curve hits £50m spend ahead of UK launch
“Coffee, networking and productivity”: Workspace disruptor ‘Lounge’ launches in London
Kompli-Global’s Technology Will Make Life Harder for Money Launderers

Oxford BioTherapeutics secures $10m from Silicon Valley Bank


Oxford BioTherapeutics has secured a $10m capital term loan from Silicon Valley Bank to accelerate the expansion of its research and development efforts.

OBT is an international clinical stage biotechnology company focused on developing innovative antibody based therapeutics, including antibody-drug conjugates, to treat cancer and other diseases.

OBT uses the optimal combination of technologies in ADC development through its collaborations with leading companies in the field and its novel OGAP target discovery system – one of the largest of its kind in the world – to provide a unique range of validated, novel antigen targets.

Meet Angelica Anton, the ex-NASA, Oxford graduate who now heads up a $500m tech fund

Christian Rohlff, CEO of Oxford BioTherapeutics, said: “This additional financial support will enable Oxford BioTherapeutics to accelerate the development of our medicines.

“With a long history of supporting life science businesses, Silicon Valley Bank is a valuable partner that recognises Oxford BioTherapeutics’ ability to transform the treatment of cancer and other diseases in an innovative way.”

Nooman Haque, director of UK life sciences and healthcare for Silicon Valley Bank, added: “Silicon Valley Bank is working alongside leading UK life science businesses, like Oxford BioTherapeutics, to provide financial solutions that support this sector’s ambitions to bring innovative therapies to the market.

“This financing demonstrates Silicon Valley Bank’s unique ability to work with businesses like Oxford BioTherapeutics by complementing their equity financing to provide an efficient solution to help stimulate their growth.”

The financing will provide $10m in capital, with $5m being funded immediately. The debt will complement new equity the company is raising.

Enter your email address to receive updates straight to your inbox

* indicates required
Send me news on...

Editor's picks


Iris Capital launches €250m European tech investment fund
posted 14 hours ago

Startup Weekly: Welsh tech accelerator calls for applications, Virgin StartUp partners with WeWork and more
posted 17 hours ago

Culture. There’s no app for that, Kalanick
posted 19 hours ago

startup life

Uber’s CEO resigns, over £368m in UK tech funding, a new $3.3bn fund and more in The Week in Tech
posted 22 hours ago


EXCLUSIVE: London-based Inploi raises £500,000, brings total to £1m
posted on June 22, 2017


UK-founded tech startup Blockchain secures $40m Series B
posted on June 22, 2017